Skip to contentI
Inhibitor Therapeutics, Inc.
I
INTIInhibitor Therapeutics, Inc. Q3 2018 · 10-Q
Revenue—
Net Income-$1.17M-$1.17MN/M vs Q3 2017 EPS Diluted$0.00$0.00— vs Q3 2017 Operating Income-$1,175,525N/M Operating Cash Flowderived-$954,931N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inhibitor Therapeutics, Inc. · CIK 1042418 · Engraved from SEC EDGAR
ended Sep 30, 2018 · filed Nov 14, 2018 · 45 d after period end